Supplementary information of "Batch effects removal for microbiome data via conditional quantile regression"

Wodan Ling, Jiuyao Lu, Ni Zhao* , Anju Lulla, Anna M. Plantinga, Weijia Fu, Angela Zhang, Hongjiao Liu, Hoseung Song, Zhigang Li, Jun Chen, Timothy W. Randolph, Wei Li A. Koay, James R. White, Lenore J. Launer, Anthony A. Fodor, Katie A. Meyer, and Michael C. Wu*

Additional details of methods

Conditional quantiles of microbial counts Y_i .

By Model (2), we model a fine sequence of conditional quantiles of $W_i|Y_i > 0$. Due to the one-to-one relationship between quantiles of $W_i|Y_i > 0$ and quantiles of $Y_i|Y_i > 0^1$, together with Model (1), we have the entire conditional quantile function of Y_i piecewise defined,

$$
Q_{Y_i}(\tau | X_i) = I\{\tau > 1 - \pi(\theta^L, X_i)\} \cdot [X_i^T \theta^Q \circ \Gamma(\tau; X_i, \theta^L) - 1], \quad \text{(Supp. 1)}
$$

where $\pi(\theta^L, X_i) = P(Y_i > 0 | X_i)$ and $\Gamma(\tau; X_i, \theta^L)$: $(1 - \pi(\theta^L, X_i), 1) \rightarrow (0, 1)$ is a one-to-one mapping from the target quantile level τ of Y_i to the nominal quantile level τ_s of $W_i|Y_i > 0$ in Model (2). Specifically, for a τ below the change point $\pi(\theta^L, X_i)$, the outcome Y_i falls in the "absence range", thus its corresponding quantile is zero. For a τ beyond the change point, $\Gamma(\tau; X_i, \theta^L)$ tells which quantile of $W_i | Y_i > 0$ determine the value of Y_i at τ . Mathematically,

$$
\theta^Q \circ \Gamma(\tau; X_i, \theta^L) = \theta^Q(\tau_s), \tau_s = \Gamma(\tau; X_i, \theta^L) = \frac{\tau - \{1 - \pi(\theta^L, X_i)\}}{\pi(\theta^L, X_i)},
$$

and the mapping is derived by

$$
\tau = P\{Y_i \le Q_{Y_i}(\tau | \mathbf{X}_i) | \mathbf{X}_i\}
$$

= {1 - $\pi(\mathbf{\theta}^L, \mathbf{X}_i)$ } + $\pi(\mathbf{\theta}^L, \mathbf{X}_i) P\{W_i \le [Q_{W_i}(\tau_s | \mathbf{X}_i, Y_i > 0) - 1] + U | \mathbf{X}_i, Y_i > 0\}.$

Apart from the characteristics mentioned in the manuscript, another merit of the twopart quantile regression model is that it allows nonlinear associations between quantiles of Y_i and the covariates X_i , though the logit of probability being present, and every quantile of the non-zero part are modelled by linear models. To give a concrete example, suppose that for one subject, the true likelihood of the investigated taxon being present in his gut (from Model (1)) is $\pi = 0.8$. Based on the mapping function above, the conditional median abundance of this taxon is determined by the $\tau_s = \frac{0.5-(1-0.8)}{0.8} = 0.38$ th quantile of W_i . If we change his assignment from placebo to treatment, how would the conditional median of the taxon abundance change accordingly? Suppose the true probability of having the taxon increases to π = 0.9 after he receives treatment. The conditional median would then be determined by the $\tau_s = \frac{0.5-(1-0.9)}{0.9} = 0.44$ th quantile of W_i . The difference in conditional median is thus nonlinear, which is a composite effect from the two parts.

Piecewise estimation strategy.

Parameters of the two-part model (1)(2) can be readily estimated by regressing $I(Y_i > 0)$ on X_i using logistic regression and regressing the non-zero Y_i on the corresponding X_i using linear quantile regression. As the variance of quantile regression estimate is inverse proportional to the local density, i.e., $var\{\widehat{\theta}^{\mathbb{Q}}(\tau)\}\to\infty$ as $\tau\to 0$, the quantile estimate is not stable at the change point $1 - \pi(\theta^L, X_i)$, and might blow up to a value with extraordinarily large magnitude. To achieve a reliable estimation of the conditional quantile function \hat{Q} , we use a piecewise strategy:

- 1. Estimate the probability of presence, $\pi(\widehat{\theta}^L, X_i) = \exp(X_i^T \widehat{\theta}^L) / \{1 + \exp(X_i^T \widehat{\theta}^L)\}\$
- 2. Select a constant $\delta \in (0, \frac{1}{2})$ $\frac{1}{2}$), divide the support of the target quantile levels (0,1) of Y_i into three sub-intervals:

$$
A_n = \{\tau: 0 < \tau < 1 - \pi(\widehat{\theta}^L, \mathbf{X}_i)\},
$$
\n
$$
B_n = \{\tau: 1 - \pi(\widehat{\theta}^L, \mathbf{X}_i) \le \tau \le 1 - \pi(\widehat{\theta}^L, \mathbf{X}_i) + n^{-\delta}\},
$$
\n
$$
C_n = \{\tau: 1 - \pi(\widehat{\theta}^L, \mathbf{X}_i) + n^{-\delta} < \tau < 1\}.
$$

3. If τ is in B_n , estimate the quantile coefficients $\widehat{\theta}^Q$ at the nominal quantile level $\Gamma(1 - \pi(\hat{\theta}^L, X_i) + n^{-\delta}; X_i, \hat{\theta}^L)$ and perform an interpolation between the quantile estimate and 1, which is the natural lower bound for microbial read count, at the change point $1 - \pi(\widehat{\theta}^{L}, X_i)$. Pick the interpolated value at τ . If τ is in C_n , estimate the $\widehat{\theta}^{Q}$ at $\Gamma(\tau; X_i, \widehat{\theta}^{L})$ directly. If linear interpolation is used, the estimation of \widehat{Q} is shown as Supp. Fig. 1, and mathematically is

$$
\hat{Q} = 0 \cdot I(\tau \in A_n)
$$
\n
$$
+ \left[\{ \mathbf{X}_i^T \hat{\boldsymbol{\theta}}^Q \circ \Gamma \left(1 - \pi \left(\hat{\boldsymbol{\theta}}^L, \mathbf{X}_i \right) + n^{-\delta}; \mathbf{X}_i, \hat{\boldsymbol{\theta}}^L \right) - 1 \} \cdot \frac{\tau - \{ 1 - \pi \left(\hat{\boldsymbol{\theta}}^L, \mathbf{X}_i \right) \}}{n^{-\delta}} \right] \cdot I(\tau \in B_n)
$$
\n
$$
+ \left[\mathbf{X}_i^T \hat{\boldsymbol{\theta}}^Q \circ \Gamma \left(\tau; \mathbf{X}_i, \hat{\boldsymbol{\theta}}^L \right) - 1 \right] \cdot I(\tau \in C_n) \tag{Supp. 2}
$$

Intuitively, the buffer zone B_n avoids the need to estimate the minimal quantiles of the non-zero part, preventing an explosive estimate around the zero-positive change point. The width of B_n , $n^{-\delta}$, is designed to converge more slowly than the logistic estimates, so the buffer will work and \hat{Q} is bounded and reliable almost surely. The consistency of \hat{Q} can be found elsewhere². Other smooth methods can be used instead of the linear interpolation, to further control the estimate around the change point. There is a tradeoff when determining the width of B_n . A wider B_n controls the estimates well but the longer interpolation introduces more biases. While if B_n is too narrow, the estimates close to the change point might not be properly controlled. Practically, when the sample size is reasonably large, we use a value approaching $\frac{1}{2}$ as δ , such as 0.499. As a complement to Fig. 1b, the matching process on the piecewise estimated conditional quantile functions is depicted in Supp. Fig. 2.

However, when the sample size is severely limited, we might opt to omit the buffer zone B_n in estimation. A small sample size leads to a wide B_n , then the interpolation in B_n will induce substantial biases. In such extreme cases, reducing the biases is our primary goal, instead of controlling the explosive estimates that might occur.

Figures and tables

Supp. Fig. 1 | Piecewise estimation of conditional quantile function.

Supp. Fig. 2 | Correction with conditional quantile functions. a, Converting a non-zero count to the corrected non-zero count at the same quantile level. **b,** Converting a zero count to a non-zero count when the batch-free distribution is less sparse. Rounded average of all matched quantiles in the batch-free distribution is taken as the adjusted read count.

a

Supp. Fig. 3 | Simulation setting, workflow, and visualization of simulated data. a, Workflow of generating simulated data based on the starting data. Specification of fold change (FC) and odds ratio (OR) are provided in Results – Evaluation on simulated data. Rounded $Y_{ij,B}''$ is the simulated (bootstrapped) count of the j-th taxon in the i-th sample. The starting data only comprises the subset of MOMS-PI with body site = vaginal and visit = 4, and with samples having less than 4000 library size and rare taxa presenting in less than 5% samples filtered out. **b,** Zero rates of the 20 chosen DA taxa in the starting data. The most abundant 5 taxa in the 20 are set to be negatively associated with Condition, because if they are set to be positively associated, their multiplied counts will be too large to maintain

libsize. **c,** PCoA plots of one simulated data for each of the six scenarios. In either Bray-Curtis or Aitchison dissimilarly, the visualization and PERMANOVA $R²$ clearly show the three patterns, Null (Scenario A), Condition Effect > Batch Effect (Scenario B), and Condition Effect < Batch Effect (Scenario C). Scenario D, E, and F show similar patterns, respectively, with increased Batch Effect incorporating library size variability.

FDR & Sensitivity, Nominal FDR=0.1

Nulls are allocated together, followed by Condition Effect > Batch Effect, and then Condition Effect < Batch Effect. Color and the name of the corresponding method are shown on the right within the graph. The solid line is FDR and the dashed line is sensitivity. Approaches with FDR attained around the nominal level 0.01 or 0.1 are valid, then among the valid approaches, the higher sensitivity is preferred.

Supp. Fig. 5 | PCoA plots of CARDIA data clustered by batch ID on taxa with different **prevalence.** Corresponding colors of the batches are shown at the bottom within the graph. **a,** by Bray-Curtis dissimilarity on raw counts of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05. Each point represents a sample with non-zero abundance for the taxa (note that fewer samples will have non-zero abundance for rarer taxa). Each ellipse represents a batch with the centroid indicating the mean. As an ellipse connects the 95% percentile of points for each batch, the size of the ellipse indicates the dispersion, and the angle indicates higher-order features of the batch. The more alignment of the ellipses is preferred. **b,** by Aitchison dissimilarity on the corresponding relative abundance of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05. **c,** by GUniFrac dissimilarity

on the corresponding relative abundance of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, $0.1 - 0.25, 0.05 - 0.1, \le 0.05$.

Supp. Fig. 6 | PCoA plots of HIVRC data clustered by study ID on taxa with different **prevalence.** Corresponding colors of the studies are shown at the bottom within the graph. **a**, by Bray-Curtis dissimilarity on raw counts of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05. Each point represents a sample with non-zero abundance for the taxa (note that fewer samples will have non-zero abundance for rarer taxa). Each ellipse represents a batch with the centroid indicating the mean. As an ellipse connects the 95% percentile of points for each batch, the size of the ellipse indicates the dispersion, and the angle indicates higher-order features of the batch. The more alignment of the ellipses is preferred. **b,** by Aitchison dissimilarity on the corresponding relative abundance of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05.

Supp. Fig. 7 | PCoA plots of MOUTH data clustered by batch ID on taxa with different **prevalence.** Corresponding colors of the batches are shown at the bottom within the graph. **a**, by Bray-Curtis dissimilarity on raw counts of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05. Each point represents a sample with non-zero abundance for the taxa (note that fewer samples will have non-zero abundance for rarer taxa). Each ellipse represents a batch with the centroid indicating the mean. As an ellipse connects the 95% percentile of points for each batch, the size of the ellipse indicates the dispersion, and the angle indicates higher-order features of the batch. The more alignment of the ellipses is preferred. **b,** by Aitchison dissimilarity on the corresponding relative abundance of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, 0.1-0.25, 0.05-0.1, <0.05. **c,** by GUniFrac dissimilarity

on the corresponding relative abundance of taxa with prevalence >0.75, 0.5-0.75, 0.25-0.5, $0.1 - 0.25, 0.05 - 0.1, \leq 0.05$.

Supp. Fig. 8 | PCoA plots of corrected data by standard ConQuR and ConQuR-libsize without fine-tuning. Corresponding colors of the batches/studies are shown at the bottom within the graph. **a,** CARDIA data, by Bray-Curtis dissimilarity on raw counts, Aitchison and GUniFrac dissimilarities on the corresponding relative abundance. Each point represents a sample, and each ellipse represents a batch with the centroid indicating the mean. As an ellipse connects the 95% percentile of points for each batch, the size of the ellipse indicates the dispersion, and the angle indicates higher-order features of the batch. The more alignment of the ellipses is preferred. **b,** HIVRC data, by Bray-Curtis dissimilarity on raw counts, Aitchison dissimilarity on the corresponding relative abundance. **c,** MOUTH data, by Bray-Curtis dissimilarity on raw counts, Aitchison and GUniFrac dissimilarities on the corresponding relative abundance.

Batch	Sample size	Library size	# Genera	SBP	Gender	Race
ID				(mean (SD))	$= 1 (%)$	$= 1 (%)$
$\mathbf{0}$	96	67716-139803	258	118.00 (16.99)	48 (50.0)	60(62.5)
	89	53287-117222	241	117.82 (13.59)	52(58.4)	61(68.5)
$\overline{2}$	90	61703-112177	237	121.11 (15.70)	47(52.2)	44 (48.9)
3	82	69760-124721	262	119.21 (14.37)	42(51.2)	47(57.3)
4	94	84358-193182	259	119.55 (17.21)	48(51.1)	46(48.9)
5	94	90841-224737	280	121.35 (17.02)	56 (59.6)	46(48.9)
6	88	71850-253856	277	117.94(17.17)	57(64.8)	45(51.1)
			Shared: 183	p -value=0.585	p -value=0.329	p -value=0.034

Supp. Tab. 1 | Summary of the 7 runs' microbial profiles and metadata of the CARDIA dataset.

Note: One-way ANOVA test and Pearson's Chi-squared test were used to detect whether there are significant differences in continuous (SBP) and categorial (Gender, Race) metadata, respectively, among the 7 runs.

Study	Author	Sample size	Library size	# Genera	HIV status	Age	Gender	BMI
ID					$= 1 (%)$	(mean (SD))	$= 1 (%)$	(mean (SD))
$\overline{0}$	Dillon ³	31	20000	235	18(58.1)	35.94 (10.63)	10(32.3)	25.18(4.44)
	Dinh ⁴	36	3500	157	21(58.3)	47.66 (7.80)	8(22.2)	25.45(3.15)
$\overline{2}$	Lozupone ⁵	37	5500	262	24(64.9)	36.21 (10.72)	8(21.6)	25.61(4.84)
$\overline{3}$	Monaco ⁶	110	194-10000	280	73 (66.4)	39.57 (9.77)	63(57.3)	24.33 (4.48)
$\overline{4}$	Noguera-Julian 7	137	10000	295	122(89.1)	43.28 (10.12)	30(21.9)	24.15(3.02)
5	Pinto-Cardoso ⁸	42	15500	225	33 (78.6)	40.19(10.14)	8(19.0)	24.29 (4.09)
6	Serrano-Villar ⁹	43	185-1000	143	34(79.1)	41.79 (10.55)	7(16.3)	24.32(3.11)
$\overline{7}$	Vesterbacka ¹⁰	62	4000	268	47(75.8)	46.94(9.61)	31(50.0)	26.45 (4.32)
8	Villanueva-Millan ¹¹	50	20000	351	30(60.0)	47.38 (9.49)	17(34.0)	25.73(5.12)
9	Villar-Garcia ¹²	24	5000	148	24(100.0)	45.92 (9.34)	3(12.5)	23.58 (3.74)
				Shared: 65	p -value< 0.001	p -value< 0.001	p -value< 0.001	p -value=0.004

Supp. Tab. 2 | Summary of the 10 sub-studies' microbial profiles and metadata of the HIVRC dataset.

Note: One-way ANOVA test and Pearson's Chi-squared test were used to detect whether there are significant differences in continuous (Age, BMI) and categorial (HIV status, Gender) metadata, respectively, among the 10 sub-studies.

Batch ID	Sample size	Library size	$#$ Genera	HPV status	Race			Sexual orientation		
				$= 1 (%)$	$= 0 (%)$	1(%)	2(%)	$= 0 (%)$	1(%)	2(%)
$\overline{0}$	42	6721-15931	156	6(14.3)	34(81.0)	5(11.9)	3(7.1)	36(85.7)	3(7.1)	3(7.1)
	46	5340-14342	141	10(21.7)	38(82.6)	6(13.0)	2(4.3)	41 (89.1)	1(2.2)	4(8.7)
$\overline{2}$	56	7267-16694	150	8(14.3)	41(73.2)	10(17.9)	5(8.9)	49 (87.5)	3(5.4)	4(7.1)
$\overline{3}$	77	5418-13520	152	6(7.8)	63 (81.8)	9(11.7)	5(6.5)	71(92.2)	4(5.2)	2(2.6)
$\overline{4}$	89	7232-18607	179	9(10.1)	76 (85.4)	9(10.1)	4(4.5)	83 (93.3)	3(3.4)	3(3.4)
5 ⁵	89	2670-18610	187	14(15.7)	50(56.2)	28(31.5)	11(12.4)	68 (76.4)	8(9.0)	13(14.6)
6	87	6534-21761	174	13(14.9)	64 (73.6)	20(23.0)	3(3.4)	74(85.1)	8(9.2)	5(5.7)
			Shared: 112	p -value=0.396	p -value=0.003			p -value=0.104		

Supp. Tab. 3 | Summary of the 7 runs' microbial profiles and metadata of the MOUTH dataset.

Note: One-way ANOVA test and Pearson's Chi-squared test were used to detect whether there are significant differences in the categorial (HPV status, Race, Sexual orientation, Smoking status) metadata among the 7 runs.

Batch ID	Sample	Smoking status					
	size	$= 0 (%)$	1(%)	2(%)			
$\boldsymbol{0}$	42	24(57.1)	14(33.3)	4(9.5)			
$\mathbf{1}$	46	29(63.0)	12(26.1)	5(10.9)			
$\overline{2}$	56	31(55.4)	20(35.7)	5(8.9)			
$\overline{3}$	77	46(59.7)	25(32.5)	6(7.8)			
$\overline{4}$	89	55 (61.8)	25(28.1)	9(10.1)			
5	89	50(56.2)	23(25.8)	16(18.0)			
6	87	45(51.7)	27(31.0)	15(17.2)			
		p -value=0.661					

Supp. Tab. 3 (cont.) | Summary of the 7 runs' microbial profiles and metadata of the MOUTH dataset.

Note: One-way ANOVA test and Pearson's Chi-squared test were used to detect whether there are significant differences in the categorial (HPV status, Race, Sexual orientation, Smoking status) metadata among the 7 runs.

Supp. Tab. 4 | Fitting strategies selected for taxa with different prevalence by fine-tuned ConQuR and ConQuR-libsize on the CARDIA data.

Note: To interpret the model, e.g., for taxa with prevalence < 0.1 in CARDIA, the optimal choice is to keep the original data; for taxa with 0.1 < prevalence < 0.2, ConQuR / ConQuR-libsize with logistic-LASSO, quantile-LASSO (with $\lambda = \frac{2p}{n}$), without interpolation in the piece-wise estimation strategy is selected; for taxa with 0.5 < prevalence < 0.6, ConQuR / ConQuR-libsize with standard logistic, quantile-LASSO (with $\lambda = \frac{2p}{n}$, with interpolation in the piece-wise estimation strategy is selected; for taxa with 0.7 < prevalence < 0.8, ConQuR / ConQuR-libsize with simple quantile-quantile matching is selected.

Supp. Tab. 5 | Fitting strategies selected for taxa with different prevalence by fine-tuned ConQuR and ConQuR-libsize on the HIVRC data.

Note: To interpret the model, e.g., for taxa with prevalence < 0.1 in HIVRC, the optimal choice is to keep the original data; for taxa with 0.1 < prevalence < 0.2, ConQuR / ConQuR-libsize with logistic-LASSO, quantile-LASSO (with $\lambda = \frac{2p}{\log n}$), without interpolation in the piece-wise estimation strategy is selected; for taxa with 0.2 < prevalence < 0.3, ConQuR / ConQuR-libsize with logistic-LASSO, composite quantile (with $\lambda = \frac{2p}{\log n}$, without interpolation in the piece-wise estimation strategy is selected; similarly for the remaining intervals of prevalence.

Supp. Tab. 6 | Fitting strategies selected for taxa with different prevalence by fine-tuned ConQuR and ConQuR-libsize on the MOUTH data.

Note: To interpret the model, e.g., for taxa with prevalence < 0.1 in MOUTH, ConQuR / ConQuR-libsize with standard logistic, quantile-LASSO (with $\lambda = \frac{2p}{n}$), without interpolation in the piece-wise estimation strategy is selected; for taxa with 0.1 < prevalence < 0.2, ConQuR / ConQuR-libsize with logistic-LASSO, quantile-LASSO (with $\lambda = \frac{2p}{\log n}$), without interpolation in the piece-wise estimation strategy is selected; for taxa with 0.2 < prevalence < 0.3, ConQuR / ConQuR-libsize with logistic-LASSO, quantile-LASSO (with $\lambda = \frac{2p}{n}$), with interpolation in the piece-wise estimation strategy is selected; similarly for the remaining intervals of prevalence.

References

- 1. Machado, J.A.F. & Silva, J.S. Quantiles for counts. *Journal of the American Statistical Association* **100**, 1226-1237 (2005).
- 2. Ling, W., Cheng, B., Wei, Y., Willey, J.Z. & Cheung, Y.K. Statistical inference in quantile regression for zero-inflated outcomes. *Statistica Sinica* **32**, 1411-1433 (2022).
- 3. Dillon, S. et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. *Mucosal immunology* **7**, 983-994 (2014).
- 4. Dinh, D.M. et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. *The Journal of infectious diseases* **211**, 19-27 (2015).
- 5. Lozupone, C.A. et al. Alterations in the gut microbiota associated with HIV-1 infection. *Cell host & microbe* **14**, 329-339 (2013).
- 6. Monaco, C.L. et al. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. *Cell host & microbe* **19**, 311-322 (2016).
- 7. Noguera-Julian, M. et al. Gut microbiota linked to sexual preference and HIV infection. *EBioMedicine* **5**, 135-146 (2016).
- 8. Pinto-Cardoso, S. et al. Fecal bacterial communities in treated HIV infected individuals on two antiretroviral regimens. *Scientific reports* **7**, 1-10 (2017).
- 9. Serrano-Villar, S. et al. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. *Mucosal immunology* **10**, 1279- 1293 (2017).
- 10. Vesterbacka, J. et al. (Nature Publishing Group, 2017).
- 11. Villanueva‐Millán, M.J., Pérez‐Matute, P., Recio‐Fernández, E., Lezana Rosales, J.M. & Oteo, J.A. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV‐infected patients. *Journal of the International AIDS Society* **20**, 21526 (2017).
- 12. Villar-Garcia, J. et al. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: a double-blind, randomised, placebo-controlled trial. *PloS one* **12**, e0173802 (2017).